Download MendeleyIsothiazoles as active-site inhibitors of HCV NS5B polymerase
Yan, S., Appleby, T., Gunic, E., Shim, J.H., Tasu, T., Kim, H., Rong, F., Chen, H., Hamatake, R., Wu, J.Z., Hong, Z., Yao, N.(2007) Bioorg Med Chem Lett 17: 28-33
- PubMed: 17049853
- DOI: https://doi.org/10.1016/j.bmcl.2006.10.002
- Primary Citation of Related Structures:
2IJN - PubMed Abstract:
Isothiazole analogs were discovered as a novel class of active-site inhibitors of HCV NS5B polymerase. The best compound has an IC(50) of 200 nM and EC(50) of 100 nM, which is a significant improvement over the starting inhibitor (1). The X-ray complex structure of 1 with HCV NS5B was obtained at a resolution of 2.2A, revealing that the inhibitor is covalently linked with Cys 366 of the 'primer-grip'. Furthermore, it makes considerable contacts with the C-terminus, beta-loop, and more importantly, to the active-site of the enzyme. The uniqueness of this binding mode offers a new insight for the rational design of novel inhibitors for HCV NS5B polymerase.
Organizational Affiliation:
Valeant Pharmaceutical Research and Development, 3300 Hyland Ave., Costa Mesa, CA 92626, USA. syan@valeant.com
